Recipharm has announces that it has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105.
RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion. Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply. RHB-105 is a new and proprietary fixed-dose oral combination therapy of two antibiotics (amoxicillian and rifabutin) and a proton pump inhibitor (omeprazole) combined into an all-in-one oral capsule with a planned indication for treatment of H. pylori infection. In June of this year, RHB-105 successfully met its primary endpoint in its first Phase III study.
This complex project straddles and integrates three of Recipharm’s manufacturing facilities making it the first project of its kind within the organization. The FDA approved facilities in Fontaine and Pessac will manufacture the Omeprazole mini-tablets, whilst in Strangnäs the final product will be encapsulated and packaged ready for final release. In order to support this project, Recipharm will invest approximately 13M SEK (1.55M USD) in manufacturing capabilities. In addition, the Strängnäs facility will be registered with the U.S. FDA. Commercial supply is expected to commence with initial launch into the U.S. market, after regulatory approval by U.S. FDA. Supply to E.U. markets is anticipated after this upon EU regulatory approval.
“This is a fantastic example of how Recipharm has been able to offer an integrated solution to solve a complex manufacturing project. We are looking forward to working on this project and supporting a successful clinical trial and launch of RHB-105,” said Erik Haeffler, VP Manufacturing services Recipharm.